The IPC GPP Training is a five-part educational series designed to provide clinicians with a practical foundation in the diagnosis, assessment, and evaluation of Generalized Pustular Psoriasis (GPP). Through a combination of expert-led educational videos and case-based exercises, participants will build confidence in recognizing and assessing GPP in clinical practice.
By the end of this training program, participants will be able to:
This training program is designed as a sequential learning experience that participants may complete at their own pace. All five modules are freely accessible, and participants may choose to watch the educational content with or without completing the assessments.
For those seeking a Certificate of Completion, an assessment follows each module. Participants must complete all five assessments and achieve a score of 80% or higher on each assessment to earn the certificate. The assessments are designed to reinforce key concepts and support mastery of the core competencies presented throughout the course.
This module introduces the IPC consensus definition and diagnostic criteria for generalized pustular psoriasis (GPP) and shows how the condition differs from chronic plaque psoriasis in presentation, genetics, and immunopathogenesis. It also reviews current and pipeline treatment options, including spesolimab trial data and off-label therapies.
This module walks through conditions that can mimic GPP, including bacterial, viral, and fungal infections, AGEP, Sneddon-Wilkinson disease, pemphigus, linear IgA bullous dermatosis, and DIRA. Clinical photos and histopathology highlight the features that distinguish each condition from GPP.
This module covers the GPPGA and GPPASI tools for scoring the cutaneous severity of GPP and the Japanese Dermatological Association criteria for evaluating systemic involvement. It also discusses incorporating patient-reported outcomes, such as fatigue, into a full severity assessment.
This module is a hands-on training on the GPPGA and GPPASI scoring tools, walking through the grading criteria for erythema, pustules, and scaling with extensive practice cases and photo examples.
This module applies the GPPGA and GPPASI tools from Module 4 to real patient case studies, working through each scoring calculation step by step. It reinforces practical scoring proficiency through worked examples.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
